Surgery Websites
LiverSource »  Faculty »  Hepatology »  Neil Mehta, M.D.
Neil Mehta, M.D.

Neil Mehta, M.D.

  • Associate Professor of Medicine General Hepatology and Liver Transplantation Department of Medicine

Contact Information

Academic Office
Division of Gastroenterology
513 Parnassus Avenue, Room S-357     
San Francisco, CA 94143-0358
(415) 476-6422 - Phone
(415) 476-0659 - Fax
Open Popup

Education

Johns Hopkins University, BA, Neuroscience, 1998-2002

University of California, San Francisco School of Medicine, MD, 2002-2006

Residencies

  • Hospital of the University of Pennsylvania, Intern, Internal Medicine, 2006-2007
  • Hospital of the University of Pennsylvania, Resident, Internal Medicine, 2007-2009

Fellowships

  • University of California, San Francisco, Fellow, Gastroenterology, 2009-2012
  • University of California, San Francisco, Fellow, Transplant Hepatology, 2012-2013

Board Certifications

  • American Board of Internal Medicine
  • American Board of Internal Medicine - Gastroenterology
  • American Board of Internal Medicine - Transplant Hepatology

Program Affiliations

  • UCSF Liver Center

Clinical Expertise

Research Interests

  • Cardiopulmonary complications of chronic liver disease
  • Hepatocellular carcinoma (HCC)
  • Liver injury and repair (Liver transplantation)
  • Liver transplantation outcomes including expanded criteria liver transplants

Biography

Dr. Neil Mehta is a general and transplant hepatologist, specializing in treating patients with hepatocellular carcinoma (HCC) and those with end-stage liver disease needing liver transplantation.

After earning his undergraduate degree from Johns Hopkins University and MD degree from UCSF, he completed residency at the Hospital of the University of Pennsylvania and both gastroenterology and advanced/transplant hepatology fellowships at UCSF. Dr. Mehta is a member of the American Association for the Study of Liver Diseases and board-certified by the American Board of Internal Medicine in Internal medicine, Gastroenterology, and Transplant Hepatology.

Research Overview

Dr. Mehta is engaged in research investigating clinical outcomes in patients with end-stage liver disease. His research focuses on two main areas:

  • Understanding issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation. Specific topics we are currently interested in are evaluating the risk of HCC recurrence post-transplant based on transplant waiting times, creating an HCC recurrence risk score, and downstaging tumors in to conventional transplant criteria.
  • Understanding the role of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

Mr. Mehta is also conducting research related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.This includes a multicenter project with CPMC and Scripps to understand the role of downstaging tumors into conventional transplant criteria. He is also pursuing projects to address the risk of HCC recurrence post-transplant based on transplant waiting times as well as to create an HCC recurrence risk score. These projects are being done collaboratively with the Mayo clinic in Rochester and Jacksonville.

Dr. Mehta is also pursuing research to help optimize the management of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 155
Data provided by UCSF Profiles, powered by CTSI
  1. Singal AG, Ghaziani TT, Mehta N, Zhou K, Grinspan LT, Benhammou JN, Moon AM, Yang JD, Salgia R, Pillai A, Zheng E, Rich NE, Gopal P, Jalal P, Verna E, Yekkaluri S, Phen S, Melendez-Torres J, Alshuwaykh O, Choi H, Junus K, Grady J, Song M, Leven EA, Yum J, Gowda V, Alsudaney M, Hernandez P, Desai N, Parikh ND. Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study. Hepatol Commun. 2023 Mar 01; 7(3). View in PubMed
  2. Wu X, Heller M, Kwong A, Fidelman N, Mehta N. Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates. J Vasc Interv Radiol. 2023 Feb 16. View in PubMed
  3. Ivanics T, Claasen MPAW, Patel MS, Giorgakis E, Khorsandi SE, Srinivasan P, Prachalias A, Menon K, Jassem W, Cortes M, Sayed BA, Mathur AK, Walker K, Taylor R, Heaton N, Mehta N, Segev DL, Massie AB, van der Meulen JHP, Sapisochin G, Wallace D. Outcomes after liver transplantation using deceased after circulatory death donors: a comparison of outcomes in the UK and the US. Liver Int. 2023 Feb 03. View in PubMed
  4. Brown AE, Shui AM, Adelmann D, Mehta N, Roll GR, Hirose R, Syed SM. Number of Local Regional Therapies for Hepatocellular Carcinoma and Peri-Operative Outcomes after Liver Transplantation. Cancers (Basel). 2023 Jan 19; 15(3). View in PubMed
  5. Qureshy Z, Lokken RP, Kakar S, Grab J, Mehta N, Sarkar M. Influence of progestin-only hormonal use on hepatocellular adenomas: A retrospective cohort study. Contraception. 2022 Dec 05; 109915. View in PubMed
  6. View All Publications

In the News

  • Mignote Yilma, M.D. to Join National Clinician Scholars Program at UCSF

    UCSF General Surgery Residency Program - Alexi Callen - December 16, 2020
    Mignote Yilma, M.D., a general surgery resident, was accepted into the National Clinician Scholars Program (NCSP) at UCSF, starting in the 2021-22 academic year. The NCSP is a prestigious two-year post-doctoral fellowship that trains scholars in community-partnered research, implementation and dissemination sciences, and health system transformation. The goal of the program is to train healthcare leaders to work in diverse settings and cultivate health equity. As one of five NCSP Scholars, Dr. [...]

  • Study Shows Excellent Post-Transplant Outcomes Following Down-Staging of HCC Patients

    UCSF Transplant Surgery - December 10, 2014
    Successful downstaging of selected patients with HCC (hepatocellular carcinoma) before liver transplantation leads to excellent 5-year recurrence-free and overall survival rates post-transplant, according to a just-reported multicenter study led by UCSF Transplant Program investigators. Medscape Medical News reported on these results at the Liver Meeting 2014: American Association for the Study of Liver Diseases (AASLD) where the UCSF study findings were presented: Treating lesions with [...]

 

 
Site Directory
    X